These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 2450411)

  • 21. Stimulated platelet aggregation, thromboxane B2 formation and platelet sensitivity to prostacyclin - a critical evaluation.
    Siess W; Roth P; Weber PC
    Thromb Haemost; 1981 Jun; 45(3):204-7. PubMed ID: 7025338
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cicaprost, an orally active prostacyclin analogue: its effects on platelet aggregation and skin blood flow in normal volunteers.
    Belch JJ; McLaren M; Lau CS; Mackay IR; Bancroft A; McEwen J; Thompson JM
    Br J Clin Pharmacol; 1993 Jun; 35(6):643-7. PubMed ID: 8329292
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Red blood cells mediate spontaneous aggregation of platelets in whole blood.
    Saniabadi AR; Lowe GD; Madhok R; Spowart K; Shaw B; Barbenel JC; Forbes CD
    Atherosclerosis; 1987 Aug; 66(3):175-80. PubMed ID: 2443148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Abnormalities of epinephrine-induced platelet aggregation and adenine nucleotides in myeloproliferative disorders.
    Yamamoto K; Sekiguchi E; Takatani O
    Thromb Haemost; 1984 Dec; 52(3):292-6. PubMed ID: 6531753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decreased platelet sensitivity to prostacyclin (epoprostenol) during hemodialysis.
    Kristensen SD; Knudsen F; Nielsen AH; Ring T
    Clin Nephrol; 1984 Apr; 21(4):230-4. PubMed ID: 6375926
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Platelet responses observed during and after infusions of the prostacyclin analog ZK 36 374.
    Yardumian DA; Mackie IJ; Bull H; Machin SJ
    Adv Prostaglandin Thromboxane Leukot Res; 1985; 13():359-62. PubMed ID: 2408446
    [No Abstract]   [Full Text] [Related]  

  • 27. Superoxide dismutase cooperates with prostacyclin to inhibit platelet aggregation: a comparative study in washed platelets and platelet rich plasma.
    Salvemini D; de Nucci G; Vane JR
    Thromb Haemost; 1991 Apr; 65(4):421-4. PubMed ID: 1647553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of equimolar concentrations of iloprost, prostacyclin, and prostaglandin E1 on human platelet function.
    Fisher CA; Kappa JR; Sinha AK; Cottrell ED; Reiser HJ; Addonizio VP
    J Lab Clin Med; 1987 Feb; 109(2):184-90. PubMed ID: 2433373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Secretory mechanisms. Behaviour of adenine nucleotides during the platelet release reaction induced by adenosine diphosphate and adrenaline.
    Holmsen H; Day HJ; Setkowsky CA
    Biochem J; 1972 Aug; 129(1):67-82. PubMed ID: 4675006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Iloprost and echistatin protect platelets during simulated extracorporeal circulation.
    Bernabei A; Gikakis N; Kowalska MA; Niewiarowski S; Edmunds LH
    Ann Thorac Surg; 1995 Jan; 59(1):149-53. PubMed ID: 7529485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Newborn platelet dysfunction: a storage pool and release defect.
    Corby DG; Zuck TF
    Thromb Haemost; 1976 Aug; 36(1):200-7. PubMed ID: 1036810
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Iloprost binding and inhibition of aggregation in platelet rich plasma. Differences between normal and type IIa hypercholesterolemic subjects.
    Oliva DW; Maderna P; Accomazzo MR; Nicosia S; Tremoli E
    Biochem Pharmacol; 1989 Jan; 38(1):39-45. PubMed ID: 2462881
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Control of human and animal platelet aggregation by a new prostacyclin analog.
    Maderna P; Colli S; Sirtori C; Tremoli E; Paoletti R
    Adv Prostaglandin Thromboxane Leukot Res; 1985; 13():363-9. PubMed ID: 2408447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target.
    Gurbel PA; Antonino MJ; Bliden KP; Dichiara J; Suarez TA; Singla A; Tantry US
    Platelets; 2008 Dec; 19(8):595-604. PubMed ID: 19012177
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Platelet impedance aggregation in whole blood and its inhibition by antiplatelet drugs.
    Mackie IJ; Jones R; Machin SJ
    J Clin Pathol; 1984 Aug; 37(8):874-8. PubMed ID: 6206096
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of the aggregation responses of camel platelets.
    Al Ghumlas AK; Gader AG
    Vet Clin Pathol; 2013 Sep; 42(3):307-13. PubMed ID: 23919654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor.
    Merritt JE; Hallam TJ; Brown AM; Boyfield I; Cooper DG; Hickey DM; Jaxa-Chamiec AA; Kaumann AJ; Keen M; Kelly E
    Br J Pharmacol; 1991 Jan; 102(1):251-9. PubMed ID: 1710526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Iloprost in peripheral vascular disease--platelet function and clinical outcome.
    Fitscha P; Tiso B; Sinzinger H
    Prog Clin Biol Res; 1987; 242():463-8. PubMed ID: 2444993
    [No Abstract]   [Full Text] [Related]  

  • 39. Inhibition of arterial thrombosis and platelet function by nafazatrom.
    Buchanan MR; Blajchman M; Hirsh J
    Thromb Res; 1982 Oct; 28(2):157-70. PubMed ID: 6758186
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Studies on inhibition of human platelet function by sodium nitroprusside. Kinetic evaluation of the effect on aggregation and cyclic nucleotide content.
    Anfossi G; Russo I; Massucco P; Mattiello L; Balbo A; Cavalot F; Trovati M
    Thromb Res; 2001 May; 102(4):319-30. PubMed ID: 11369425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.